Schadendorf, D., Ugurel, S., Rittgen, W., Edler, L., & Sucker, A. (2020). Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: A randomized phase III trial of the DC study group of the DeCOG. Annals of oncology, 17(4), . https://doi.org/10.1093/annonc/mdj138
Chicago-Zitierstil (17. Ausg.)Schadendorf, Dirk, Selma Ugurel, Werner Rittgen, Lutz Edler, und Antje Sucker. "Dacarbazine (DTIC) Versus Vaccination with Autologous Peptide-pulsed Dendritic Cells (DC) in First-line Treatment of Patients with Metastatic Melanoma: A Randomized Phase III Trial of the DC Study Group of the DeCOG." Annals of Oncology 17, no. 4 (2020). https://doi.org/10.1093/annonc/mdj138.
MLA-Zitierstil (9. Ausg.)Schadendorf, Dirk, et al. "Dacarbazine (DTIC) Versus Vaccination with Autologous Peptide-pulsed Dendritic Cells (DC) in First-line Treatment of Patients with Metastatic Melanoma: A Randomized Phase III Trial of the DC Study Group of the DeCOG." Annals of Oncology, vol. 17, no. 4, 2020, https://doi.org/10.1093/annonc/mdj138.